Skip Navigation


JAC Advance Access originally published online on April 6, 2006
Journal of Antimicrobial Chemotherapy 2006 58(1):220; doi:10.1093/jac/dkl143
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/1/220    most recent
dkl143v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leibovici, L.
Right arrow Articles by Paul, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leibovici, L.
Right arrow Articles by Paul, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Comment on Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK

Leonard Leibovici* and Mical Paul

Department of Medicine E, Beilinson Campus, Rabin Medical Center 49100 Petah-Tiqva, Israel

*Corresponding author. Tel: + 972-3-9376501; Fax: + 972-3-9376512; E-mail: leibovic@post.tau.ac.il

Keywords: Staphylococcus spp. , antibiotic policy , empirical treatment

The first 10% of the full text of this article appears below.

Sir,

In the Guidelines for prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK,1 the Joint Working Party states for empirical treatment that ‘The prevalence level at which flucloxacillin or other penicillinase-stable penicillins, . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, and on behalf of the MRSA Working Party of the British
Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom
J. Antimicrob. Chemother., May 1, 2009; 63(5): 849 - 861.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
R. A Howe
Don't include trimethoprim
BMJ, April 12, 2008; 336(7648): 787 - 787.
[Full Text] [PDF]